← brief for 2026-08-12 · Slowing decline

Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD: Target Trial Emulation Study.

Article C Peer reviewed Observational

Key takeaways

This study compared two bone-building drugs, romosozumab and teriparatide, in people who have both weak bones and chronic kidney disease. It looked back at real patient records to check heart safety, so it shows a link and cannot prove cause. It hints at how the two drugs may differ for kidney patients, but a real trial would be needed to be sure.

Who did this work

Hung CH · Yang FY · Huang HE · Wei JC

Source

Article · PubMed, CKD progression and prevention · 2026 Aug 12
https://pubmed.ncbi.nlm.nih.gov/42584962/